Current and emerging biomarkers in tumors of the central nervous system: Possible diagnostic, prognostic and therapeutic applications

Seminars in Cancer Biology

Volumn 52, Issue , 2018, Pages 85-102

  Khan, Ishaq N ^a,b   Ullah, Najeeb ^a   Hussein, Deema ^b   Saini, Kulvinder S ^b,c  

^a KHYBER MEDICAL UNIVERSITY   (Pakistan)

^b KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^c ETERNAL UNIVERSITY   (India)

Author keywords

Cancer stem cells markers; Cancer targeted therapy; Cell signalling markers; Clinical trials biomarkers; CNS tumors

Indexed keywords

CELL SURFACE MARKER; LONG UNTRANSLATED RNA; MESSENGER RNA; MICRORNA; TUMOR MARKER; CELL FREE NUCLEIC ACID;

BLOOD; BODY FLUID; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER STEM CELL; CANCER THERAPY; CELL ACTIVATION; CELL ORGANELLE; CELL SURFACE; CENTRAL NERVOUS SYSTEM TUMOR; CEREBROSPINAL FLUID; CLINICAL EVALUATION; CLINICAL RESEARCH; CYTOPLASM; EXOSOME; EXTRACELLULAR MATRIX; GENETIC TRANSCRIPTION; HUMAN; NONHUMAN; PERSONALIZED MEDICINE; REVIEW; SIGNAL TRANSDUCTION; URINE; GENETICS; METABOLISM; MUTATION; PATHOLOGY; PROGNOSIS;

BIOMARKERS, TUMOR; CELL-FREE NUCLEIC ACIDS; CENTRAL NERVOUS SYSTEM NEOPLASMS; EXOSOMES; HUMANS; MICRORNAS; MUTATION; NEOPLASTIC STEM CELLS; PROGNOSIS; RNA, LONG NONCODING;

EID: 85026794747     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2017.07.004     Document Type: Review

References (175)

1. Catalona, W.J., Richie, J.P., Ahmann, F.R., M'liss, A.H., Scardino, P.T., Flanigan, R.C., DeKernion, J.B., Ratliff, T.L., Kavoussi, L.R., Dalkin, B.L., Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6630 men. J. Urol. 197:2 (2017), S200–S207.
2. Omenn, G.S., Guan, Y., Menon, R., A new class of protein cancer biomarker candidates: differentially expressed splice variants of ERBB2 (HER2/neu) and ERBB1 (EGFR) in breast cancer cell lines. J. Poteomics 107 (2014), 103–112.
3. Bresnick, A.R., Weber, D.J., Zimmer, D.B., S100 proteins in cancer. Nat. Rev. Cancer 15:2 (2015), 96–109.
4. Farinati, F., Marino, D., De Giorgio, M., Baldan, A., Cantarini, M., Cursaro, C., Rapaccini, G., Del Poggio, P., Di Nolfo, M.A., Benvegnù L., Diagnostic and prognostic role of α-fetoprotein in hepatocellular carcinoma: both or neither?. Am. J. Gastroenterol. 101:3 (2006), 524–532.
5. V. Bajic, M. Kaur, Molecular biomarker set for early detection of ovarian cancer, Google Patents, 2015.
6. Oxnard, G.R., Paweletz, C.P., Kuang, Y., Mach, S.L., O'Connell, A., Messineo, M.M., Luke, J.J., Butaney, M., Kirschmeier, P., Jackman, D.M., Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clin. Cancer Res. 20:6 (2014), 1698–1705.
7. Ye, Y.-X., Zhou, J., Zhou, Y.-H., Zhou, Y., Song, X.-B., Wang, J., Lin, L., Ying, B.-W., Lu, X.-J., Clinical significance of BCR-ABL fusion gene subtypes in chronic myelogenous and acute lymphoblastic leukemias. Asian Pac. J. Cancer Prev. 15:22 (2014), 9961–9966.
8. Huang, Z., Liu, F., Diagnostic value of serum carbohydrate antigen 19-9 in pancreatic cancer: a meta-analysis. Tumor Biol. 35:8 (2014), 7459–7465.
9. King, M.-C., Marks, J.H., Mandell, J.B., Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302:5645 (2003), 643–646.
10. Reichardt, P., Demetri, G.D., Gelderblom, H., Rutkowski, P., Im, S.-A., Gupta, S., Kang, Y.-K., Schöffski, P., Schuette, J., Soulières, D., Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial. BMC Cancer, 16(1), 2016, 22.
11. Verberne, C.J., Wiggers, T., Grossmann, I., Bock, G., Vermeulen, K., Cost-effectiveness of a carcinoembryonic antigen (CEA) based follow-up programme for colorectal cancer (the CEA Watch trial). Colorectal Dis. 18:3 (2016), O91–O96.
12. R. Dienstmann, J. Tabernero, BRAF as a target for cancer therapy, Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Cancer Agents) 11 (3) (2011) 285–295.
13. McCormick, T., Martin, K., Hehenberger, M., The Evolving Role of Biomarkers: Focusing on Patients from Research to Clinical Practice. 2007, IBM Global Business Services.
14. Printz, C., Failure rate: why many cancer drugs don't receive FDA approval, and what can be done about it. Cancer 121:10 (2015), 1529–1530.
15. Schork, N.J., Personalized medicine: time for one-person trials. Nature 520:7549 (2015), 609–611.
16. Frank, R., Hargreaves, R., Clinical biomarkers in drug discovery and development. Nat. Rev. Drug Discov. 2:7 (2003), 566–580.
17. Woodcock, J., The prospects for personalized medicine in drug development and drug therapy. Clin. Pharmacol. Ther. 81:2 (2007), 164–169.
18. Kalinina, J., Peng, J., Ritchie, J.C., Van Meir, E.G., Proteomics of gliomas: initial biomarker discovery and evolution of technology. Neuro-Oncol. 13:9 (2011), 926–942.
19. Khan, I., Bangash, M., Baeesa, S., Jamal, A., Carracedo, A., Alghamdi, F., Qashqari, H., Abuzenadah, A., AlQahtani, M., Damanhouri, G., Epidemiological trends of histopathologically WHO classified CNS tumors in developing countries: systematic review. Asian Pac. J. Cancer Prev. 16:1 (2015), 205–216.
20. Lee, J.-K., Wang, J., Sa, J.K., Ladewig, E., Lee, H.-O., Lee, I.-H., Kang, H.J., Rosenbloom, D.S., Camara, P.G., Liu, Z., Spatiotemporal genomic architecture informs precision oncology in glioblastoma. Nat. Genet., 2017.
21. Louis, D.N., Perry, A., Reifenberger, G., von Deimling, A., Figarella-Branger, D., Cavenee, W.K., Ohgaki, H., Wiestler, O.D., Kleihues, P., Ellison, D.W., The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. (Berl.) 131:6 (2016), 803–820.
22. Weller, M., Stupp, R., Hegi, M.E., van den Bent, M., Tonn, J.C., Sanson, M., Wick, W., Reifenberger, G., Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice. Neuro-Oncol. 14:Suppl. 4 (2012), iv100–iv108.
23. Hanahan, D., Weinberg, R.A., Hallmarks of cancer: the next generation. Cell 144:5 (2011), 646–674.
24. Verhaak, R.G., Hoadley, K.A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M.D., Miller, C.R., Ding, L., Golub, T., Mesirov, J.P., Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17:1 (2010), 98–110.
25. Reya, T., Morrison, S.J., Clarke, M.F., Weissman, I.L., Stem cells, cancer, and cancer stem cells. Nature 414:6859 (2001), 105–111.
26. Harrison, R.A., de Groot, J.F., Cell signaling pathways in brain tumors. Top. Magn. Reson. Imaging 26:1 (2017), 15–26.
27. Deller, M.C., Jones, E.Y., Cell surface receptors. Curr. Opin. Struct. Biol. 10:2 (2000), 213–219.
28. Machein, M.R., Plate, K.H., VEGF in brain tumors. J. Neurooncol. 50:1–2 (2000), 109–120.
29. proteinatlas.org, The Human Protein Atlas, 2017. www.proteinatlas.org. (Accessed March 2017).
30. ClinicalTrials.gov, Clinical trials identifers, 2017. www.clinicaltrials.gov. (Accessed June, 2017).
31. Gan, H.K., Kaye, A.H., Luwor, R.B., The EGFRvIII variant in glioblastoma multiforme. J. Clin. Neurosci. 16:6 (2009), 748–754.
32. Pietras, K., Sjöblom, T., Rubin, K., Heldin, C.-H., Östman, A., PDGF receptors as cancer drug targets. Cancer Cell 3:5 (2003), 439–443.
33. Paulsson, J., Ehnman, M., Östman, A., PDGF receptors in tumor biology: prognostic and predictive potential. Future Oncol. 10:9 (2014), 1695–1708.
34. Weaver, M., Laske, D.W., Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas. J. Neurooncol. 65:1 (2003), 3–14.
35. Kuan, C.-T., Wakiya, K., Dowell, J.M., Herndon, J.E., Reardon, D.A., Graner, M.W., Riggins, G.J., Wikstrand, C.J., Bigner, D.D., Glycoprotein nonmetastatic melanoma protein B, a potential molecular therapeutic target in patients with glioblastoma multiforme. Clin. Cancer Res. 12:7 (2006), 1970–1982.
36. Foehr, E.D., Lorente, G., Kuo, J., Ram, R., Nikolich, K., Urfer, R., Targeting of the receptor protein tyrosine phosphatase β with a monoclonal antibody delays tumor growth in a glioblastoma model. Cancer Res. 66:4 (2006), 2271–2278.
37. Chandramohan, V., Bao, X., Kato Kaneko, M., Kato, Y., Keir, S.T., Szafranski, S.E., Kuan, C.T., Pastan, I.H., Bigner, D.D., Recombinant anti-podoplanin (NZ-1) immunotoxin for the treatment of malignant brain tumors. Int. J. Cancer 132:10 (2013), 2339–2348.
38. Rustamzadeh, E., Hall, W.A., Todhunter, D.A., Vallera, V.D., Low, W.C., Liu, H., Panoskaltsis-Mortari, A., Vallera, D.A., Intracranial therapy of glioblastoma with the fusion protein DTAT in immunodeficient mice. Int. J. Cancer 120:2 (2007), 411–419.
39. Kuan, C.T., Srivastava, N., McLendon, R.E., Marasco, W.A., Zalutsky, M.R., Bigner, D.D., Recombinant single-chain variable fragment antibodies against extracellular epitopes of human multidrug resistance protein MRP3 for targeting malignant gliomas. Int. J. Cancer 127:3 (2010), 598–611.
40. Dai, S., Wang, X., Li, X., Cao, Y., MicroRNA-139-5p acts as a tumor suppressor by targeting ELTD1 and regulating cell cycle in glioblastoma multiforme. Biochem. Biophys. Res. Commun. 467:2 (2015), 204–210.
41. Ziegler, J., Pody, R., de Souza, P.C., Evans, B., Saunders, D., Smith, N., Mallory, S., Njoku, C., Dong, Y., Chen, H., ELTD1, an effective anti-angiogenic target for gliomas: preclinical assessment in mouse GL261 and human G55 xenograft glioma models. Neuro-Oncol., 2016 (now147).
42. Le, A.P., Huang, Y., Pingle, S.C., Kesari, S., Wang, H., Yong, R.L., Zou, H., Friedel, R.H., Plexin-B2 promotes invasive growth of malignant glioma. Oncotarget, 6(9), 2015, 7293.
43. Knobbe, C.B., Reifenberger, J., Reifenberger, G., Mutation analysis of the Ras pathway genes NRAS, HRAS, KRAS and BRAF in glioblastomas. Acta Neuropathol. (Berl.) 108:6 (2004), 467–470.
44. Korshunov, A., Meyer, J., Capper, D., Christians, A., Remke, M., Witt, H., Pfister, S., von Deimling, A., Hartmann, C., Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma. Acta Neuropathol. (Berl.) 118:3 (2009), 401–405.
45. Levy, J.M.M., Thompson, J.C., Griesinger, A.M., Amani, V., Donson, A.M., Birks, D.K., Morgan, M.J., Mirsky, D.M., Handler, M.H., Foreman, N.K., Autophagy inhibition improves chemosensitivity in BRAFV600E brain tumors. Cancer Discov. 4:7 (2014), 773–780.
46. Aizer, A.A., Abedalthagafi, M., Bi, W.L., Horvath, M.C., Arvold, N.D., Al-Mefty, O., Lee, E.Q., Nayak, L., Rinne, M.L., Norden, A.D., A prognostic cytogenetic scoring system to guide the adjuvant management of patients with atypical meningioma. Neuro-Oncol. 2 (2016), 269–274.
47. Li, X., Wu, C., Chen, N., Gu, H., Yen, A., Cao, L., Wang, E., Wang, L., PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma. Oncotarget 7:22 (2016), 33440–33450.
48. Eyler, C.E., Foo, W.C., LaFiura, K.M., McLendon, R.E., Hjelmeland, A.B., Rich, J.N., Brain cancer stem cells display preferential sensitivity to Akt inhibition. Stem Cells 26:12 (2008), 3027–3036.
49. Chakravarti, A., Zhai, G., Suzuki, Y., Sarkesh, S., Black, P.M., Muzikansky, A., Loeffler, J.S., The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas. J. Clin. Oncol. 22:10 (2004), 1926–1933.
50. Steelman, L., Franklin, R., Abrams, S., Chappell, W., Kempf, C., Bäsecke, J., Stivala, F., Donia, M., Fagone, P., Nicoletti, F., Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy. Leukemia 25:7 (2011), 1080–1094.
51. Shen, X., Burguillos, M.A., Osman, A.M., Frijhoff, J., Carrillo-Jiménez, A., Kanatani, S., Augsten, M., Saidi, D., Rodhe, J., Kavanagh, E., Glioma-induced inhibition of caspase-3 in microglia promotes a tumor-supportive phenotype. Nat. Immunol. 17:11 (2016), 1282–1290.
52. McDonald, K.L., O'sullivan, M.G., Parkinson, J.F., Shaw, J.M., Payne, C.A., Brewer, J.M., Young, L., Reader, D.J., Wheeler, H.T., Cook, R.J., IQGAP1 and IGFBP2 valuable biomarkers for determining prognosis in glioma patients. J. Neuropathol. Exp. Neurol. 66:5 (2007), 405–417.
53. Kodiha, M., Wang, Y.M., Hutter, E., Maysinger, D., Stochaj, U., Off to the organelles-killing cancer cells with targeted gold nanoparticles. Theranostics 5:4 (2015), 357–370.
54. Kondo, Y., Kanzawa, T., Sawaya, R., Kondo, S., The role of autophagy in cancer development and response to therapy. Nat. Rev. Cancer 5:9 (2005), 726–734.
55. Golovnina, K., Blinov, A., Akhmametyeva, E.M., Omelyanchuk, L.V., Chang, L.-S., Evolution and origin of merlin, the product of the Neurofibromatosis type 2 (NF2) tumor-suppressor gene. BMC Evol. Biol., 5(1), 2005, 69.
56. Goplen, D., Wang, J., Enger, P.Ø., Tysnes, B.B., Terzis, A., Laerum, O.D., Bjerkvig, R., Protein disulfide isomerase expression is related to the invasive properties of malignant glioma. Cancer Res. 66:20 (2006), 9895–9902.
57. Morano, K.A., New tricks for an old dog. Ann. N. Y. Acad. Sci. 1113:1 (2007), 1–14.
58. Shevtsov, M., Stangl, S., Riederer, I., Sievert, W., Parr, M., Marchenko, Y., Yakovleva, L., Nikolaev, B., Ryzhov, V., Multhoff, G., P07. 20 Combination of the radiotherapy and targeted magnetic nanoparticles in the theranostics of the Hsp70-positive brain tumors. Neuro-Oncol. 18:Suppl. 4 (2016), iv38–iv39.
59. Shevtsov, M.A., Nikolaev, B.P., Ryzhov, V.A., Yakovleva, L.Y., Dobrodumov, A.V., Marchenko, Y.Y., Margulis, B.A., Pitkin, E., Guzhova, I.V., Brain tumor magnetic targeting and biodistribution of superparamagnetic iron oxide nanoparticles linked with 70-kDa heat shock protein study by nonlinear longitudinal response. J. Magn. Magn. Mater. 388 (2015), 123–134.
60. Shevtsov, M.A., Yakovleva, L.Y., Nikolaev, B.P., Marchenko, Y.Y., Dobrodumov, A.V., Onokhin, K.V., Onokhina, Y.S., Selkov, S.A., Mikhrina, A.L., Guzhova, I.V., Tumor targeting using magnetic nanoparticle Hsp70 conjugate in a model of C6 glioma. Neuro-Oncol. 16:1 (2014), 38–49.
61. Ding, J., Liu, B., He, Y., Yuan, X., Tian, D., Ji, B., Wang, L., Wu, L., Dong, H., Wang, J., LRIG1 improves chemosensitivity through inhibition of BCL-2 and MnSOD in glioblastoma. Cell Biochem. Biophys. 71:1 (2015), 27–33.
62. Aaberg-Jessen, C., Halle, B., Jensen, S.S., Müller, S., Rømer, U.M., Pedersen, C.B., Brünner, N., Kristensen, B.W., Comparative studies of TIMP-1 immunohistochemistry, TIMP-1 FISH analysis and plasma TIMP-1 in glioblastoma patients. J. Neurooncol. 130:3 (2016), 439–448.
63. Aaberg-Jessen, C., Christensen, K., Offenberg, H., Bartels, A., Dreehsen, T., Hansen, S., Schrøder, H.D., Brünner, N., Kristensen, B.W., Low expression of tissue inhibitor of metalloproteinases-1 (TIMP-1) in glioblastoma predicts longer patient survival. J. Neurooncol., 95(1), 2009, 117.
64. Yamaoka, K., Mishima, K., Nagashima, Y., Asai, A., Sanai, Y., Kirino, T., Expression of galectin-1 mRNA correlates with the malignant potential of human gliomas and expression of antisense galectin-1 inhibits the growth of 9 glioma cells. J. Neurosci. Res. 59:6 (2000), 722–730.
65. Neder, L., Marie, S.K.N., Carlotti, C.G., Gabbai, A.A., Rosemberg, S., Malheiros, S.M., Siqueira, R.P., Oba-Shinjo, S.M., Uno, M., Aguiar, P.H., Galectin-3 as an immunohistochemical tool to distinguish pilocytic astrocytomas from diffuse astrocytomas, and glioblastomas from anaplastic oligodendrogliomas. Brain Pathol. 14:4 (2004), 399–405.
66. Li, L., Xu, J., Davie, J., Katyal, S., Symons, M., Vanan, M.I., PTPS-29 ubiquitin carboxyl terminal hydrolase-L1 (UCH-L1) is a tumor suppressor in atypical teratoid rhabdoid tumors (ATRTs). Neuro-Oncol., 17(Suppl. 5), 2015 (v185-v185).
67. Liu, J., Guo, S., Li, Q., Yang, L., Xia, Z., Zhang, L., Huang, Z., Zhang, N., Phosphoglycerate dehydrogenase induces glioma cells proliferation and invasion by stabilizing forkhead box M1. J. Neurooncol. 111:3 (2013), 245–255.
68. Chen, W., Hu, Z., Li, X.-z., Li, J.-l., Xu, X.-K., Li, H.-g., Liu, Y., Liu, B.-h., Jia, W.-h., Li, F.-c., CPEB4 interacts with Vimentin and involves in progressive features and poor prognosis of patients with astrocytic tumors. Tumor Biol. 4 (2016), 5075–5087.
69. Griguer, C.E., Cantor, A.B., Fathallah-Shaykh, H.M., Gillespie, G.Y., Gordon, A.S., Markert, J.M., Radovanovic, I., Clement-Schatlo, V., Shannon, C.N., Oliva, C.R., Prognostic relevance of cytochrome C oxidase in primary glioblastoma multiforme. PLoS One, 8(4), 2013, e61035.
70. He, X., Lin, X., Cai, M., Fan, D., Chen, X., Wang, L., Wu, X., Lan, P., Wang, J., High expression of cytoplasmic polyadenylation element-binding protein 4 correlates with poor prognosis of patients with colorectal cancer. Virchows Arch., 2016, 1–9.
71. Khan, I.N., Al-Karim, S., Bora, R.S., Chaudhary, A.G., Saini, K.S., Cancer stem cells: a challenging paradigm for designing targeted drug therapies. Drug Discov. Today 20:10 (2015), 1205–1216.
72. miRBase, miRBase database, 2017. www.mirbase.org. (Accessed April 2017).
73. Zhi, F., Shao, N., Li, B., Xue, L., Deng, D., Xu, Y., Lan, Q., Peng, Y., Yang, Y., A serum 6-miRNA panel as a novel non-invasive biomarker for meningioma. Sci. Rep., 6, 2016.
74. Saadatpour, L., Fadaee, E., Fadaei, S., Mansour, R.N., Mohammadi, M., Mousavi, S., Goodarzi, M., Verdi, J., Mirzaei, H., Glioblastoma: exosome and microRNA as novel diagnosis biomarkers. Cancer Gene Ther. 23:12 (2016), 415–418.
75. Pang, J.C.-s., Kwok, W.K., Chen, Z., Ng, H.-K., Oncogenic role of microRNAs in brain tumors. Acta Neuropathol. (Berl.) 117:6 (2009), 599–611.
76. Mizoguchi, M., Guan, Y., Yoshimoto, K., Hata, N., Amano, T., Nakamizo, A., Sasaki, T., Clinical implications of microRNAs in human glioblastoma. Front. Oncol., 3, 2013, 19.
77. Braoudaki, M., Lambrou, G.I., Giannikou, K., Milionis, V., Stefanaki, K., Birks, D.K., Prodromou, N., Kolialexi, A., Kattamis, A., Spiliopoulou, C.A., Microrna expression signatures predict patient progression and disease outcome in pediatric embryonal central nervous system neoplasms. J. Hematol. Oncol., 7(1), 2014, 96.
78. Braoudaki, M., Lambrou, G., Papadodima, S., Stefanaki, K., Prodromou, N., Kanavakis, E., MicroRNA expression profiles in pediatric dysembryoplastic neuroepithelial tumors. Med. Oncol., 33(1), 2016, 5.
79. Guessous, F., Zhang, Y., Kofman, A., Catania, A., Li, Y., Schiff, D., Purow, B., Abounader, R., microRNA-34a is tumor suppressive in brain tumors and glioma stem cells. ABBV Cell Cycle 9:6 (2010), 1031–1036.
80. Guan, Y., Mizoguchi, M., Yoshimoto, K., Hata, N., Shono, T., Suzuki, S.O., Araki, Y., Kuga, D., Nakamizo, A., Amano, T., MiRNA-196 is upregulated in glioblastoma but not in anaplastic astrocytoma and has prognostic significance. Clin. Cancer Res. 16:16 (2010), 4289–4297.
81. Wu, Z., Sun, L., Wang, H., Yao, J., Jiang, C., Xu, W., Yang, Z., MiR-328 expression is decreased in high-grade gliomas and is associated with worse survival in primary glioblastoma. PLoS One, 7(10), 2012, e47270.
82. Kefas, B., Comeau, L., Floyd, D.H., Seleverstov, O., Godlewski, J., Schmittgen, T., Jiang, J., Li, Y., Chiocca, E.A., Lee, J., The neuronal microRNA miR-326 acts in a feedback loop with notch and has therapeutic potential against brain tumors. J. Neurosci. 29:48 (2009), 15161–15168.
83. Li, M., Lee, K.F., Lu, Y., Clarke, I., Shih, D., Eberhart, C., Collins, V.P., Van Meter, T., Picard, D., Zhou, L., Frequent amplification of a chr19q13. 41 microRNA polycistron in aggressive primitive neuroectodermal brain tumors. Cancer Cell 16:6 (2009), 533–546.
84. Chan, J.A., Krichevsky, A.M., Kosik, K.S., MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res. 65:14 (2005), 6029–6033.
85. Nass, D., Rosenwald, S., Meiri, E., Gilad, S., Tabibian-Keissar, H., Schlosberg, A., Kuker, H., Sion-Vardy, N., Tobar, A., Kharenko, O., MiR-92b and miR-9/9* are specifically expressed in brain primary tumors and can be used to differentiate primary from metastatic brain tumors. Brain Pathol. 19:3 (2009), 375–383.
86. Qiu, S., Lin, S., Hu, D., Feng, Y., Tan, Y., Peng, Y., Interactions of miR-323/miR-326/miR-329 and miR-130a/miR-155/miR-210 as prognostic indicators for clinical outcome of glioblastoma patients. J. Transl. Med., 11(1), 2013, 10.
87. Conti, A., Aguennouz, M.H., La Torre, D., Tomasello, C., Cardali, S., Angileri, F.F., Maio, F., Cama, A., Germanò A., Vita, G., miR-21 and 221 upregulation and miR-181b downregulation in human grade II?IV astrocytic tumors. J. Neurooncol. 3 (2009), 325–332.
88. Uziel, T., Karginov, F.V., Xie, S., Parker, J.S., Wang, Y.-D., Gajjar, A., He, L., Ellison, D., Gilbertson, R.J., Hannon, G., The miR-17∼92 cluster collaborates with the Sonic Hedgehog pathway in medulloblastoma. Proc. Natl. Acad. Sci. 106:8 (2009), 2812–2817.
89. Fang, X., Yoon, J.-G., Li, L., Yu, W., Shao, J., Hua, D., Zheng, S., Hood, L., Goodlett, D.R., Foltz, G., The SOX2 response program in glioblastoma multiforme: an integrated ChIP-seq, expression microarray, and microRNA analysis. BMC Genomics, 12(1), 2011, 11.
90. Birks, D.K., Barton, V.N., Donson, A.M., Handler, M.H., Vibhakar, R., Foreman, N.K., Survey of MicroRNA expression in pediatric brain tumors. Pediatr. Blood Cancer 56:2 (2011), 211–216.
91. Ciafre, S., Galardi, S., Mangiola, A., Ferracin, M., Liu, C.-G., Sabatino, G., Negrini, M., Maira, G., Croce, C., Farace, M., Extensive modulation of a set of microRNAs in primary glioblastoma. Biochem. Biophys. Res. Commun. 334:4 (2005), 1351–1358.
92. Lipovich, L., Johnson, R., Lin, C.-Y., MacroRNA underdogs in a microRNA world: evolutionary, regulatory, and biomedical significance of mammalian long non-protein-coding RNA. Biochim. Biophys. Acta (BBA)-Gene Regul. Mech. 1799:9 (2010), 597–615.
93. Mercer, T.R., Dinger, M.E., Mattick, J.S., Long non-coding RNAs: insights into functions. Nat. Rev. Genet. 10:3 (2009), 155–159.
94. Amaral, P.P., Dinger, M.E., Mercer, T.R., Mattick, J.S., The eukaryotic genome as an RNA machine. Science 319:5871 (2008), 1787–1789.
95. Min, W., Dai, D., Wang, J., Zhang, D., Zhang, Y., Han, G., Zhang, L., Chen, C., Li, X., Li, Y., Long noncoding RNA miR210HG as a potential biomarker for the diagnosis of glioma. PLoS One, 11(9), 2016, e0160451.
96. Kiang, K.M.-Y., Zhang, X.-Q., Leung, G.K.-K., Long non-coding RNAs: the key players in glioma pathogenesis. Cancers 7:3 (2015), 1406–1424.
97. Zhang, X., Sun, S., Pu, J.K.S., Tsang, A.C.O., Lee, D., Man, V.O.Y., Lui, W.M., Wong, S.T.S., Leung, G.K.K., Long non-coding RNA expression profiles predict clinical phenotypes in glioma. Neurobiol. Dis. 48:1 (2012), 1–8.
98. Li, R., Qian, J., Wang, Y.Y., Zhang, J.X., You, Y.P., Long noncoding RNA profiles reveal three molecular subtypes in glioma. CNS Neurosci. Ther. 20:4 (2014), 339–343.
99. Guo, H., Wu, L., Yang, Q., Ye, M., Zhu, X., Functional linc-POU3F3 is overexpressed and contributes to tumorigenesis in glioma. Gene 554:1 (2015), 114–119.
100. Ma, K.-x.., Wang, H.-j., Li, X.-r., Li, T., Su, G., Yang, P., Wu, J.-w., Long noncoding RNA MALAT1 associates with the malignant status and poor prognosis in glioma. Tumor Biol. 5 (2015), 3355–3359.
101. Wang, Y., Wang, Y., Li, J., Zhang, Y., Yin, H., Han, B., a long-noncoding RNA, promotes glioma cell growth and invasion through mTOR signaling. Cancer Lett. 367:2 (2015), 122–128.
102. Yao, Y., Ma, J., Xue, Y., Wang, P., Li, Z., Liu, J., Chen, L., Xi, Z., Teng, H., Wang, Z., Knockdown of long non-coding RNA XIST exerts tumor-suppressive functions in human glioblastoma stem cells by up-regulating miR-152. Cancer Lett. 359:1 (2015), 75–86.
103. Qin, X., Yao, J., Geng, P., Fu, X., Xue, J., Zhang, Z., LncRNA TSLC1-AS1 is a novel tumor suppressor in glioma. Int. J. Clin. Exp. Pathol. 7:6 (2014), 3065–3072.
104. Wang, P., Liu, Y.-h., Yao, Y.-l., Li, Z., Li, Z.-q., Ma, J., Xue, Y.-x., Long non-coding RNA CASC2 suppresses malignancy in human gliomas by miR-21. Cell. Signal. 27:2 (2015), 275–282.
105. Shi, Y., Wang, Y., Luan, W., Wang, P., Tao, T., Zhang, J., Qian, J., Liu, N., You, Y., Long non-coding RNA H19 promotes glioma cell invasion by deriving miR-675. PLoS One, 9(1), 2014, e86295.
106. Zhang, J.-X., Han, L., Bao, Z.-S., Wang, Y.-Y., Chen, L.-Y., Yan, W., Yu, S.-Z., Pu, P.-Y., Liu, N., You, Y.-P., HOTAIR, a cell cycle-associated long noncoding RNA and a strong predictor of survival, is preferentially expressed in classical and mesenchymal glioma. Neuro-Oncol., 2013 (not131).
107. Wang, P., Ren, Z., Sun, P., Overexpression of the long non-coding RNA MEG3 impairs in vitro glioma cell proliferation. J. Cell. Biochem. 113:6 (2012), 1868–1874.
108. Baritaki, S., Chatzinikola, A.M., Vakis, A.F., Soulitzis, N., Karabetsos, D.A., Neonakis, I., Bonavida, B., Spandidos, D.A., YY1 over-expression in human brain gliomas and meningiomas correlates with TGF-β1, IGF-1 and FGF-2 mRNA levels. Cancer Invest. 27:2 (2009), 184–192.
109. Jamshidi, N., Diehn, M., Bredel, M., Kuo, M.D., Illuminating radiogenomic characteristics of glioblastoma multiforme through integration of MR imaging, messenger RNA expression, and DNA copy number variation. Radiology 270:1 (2013), 1–2.
110. Alentorn, A., Duran-Peña, A., Pingle, S.C., Piccioni, D.E., Idbaih, A., Kesari, S., Molecular profiling of gliomas: potential therapeutic implications. Expert Rev. Anticancer Ther. 15:8 (2015), 955–962.
111. Eckel-Passow, J.E., Lachance, D.H., Molinaro, A.M., Walsh, K.M., Decker, P.A., Sicotte, H., Pekmezci, M., Rice, T., Kosel, M.L., Smirnov, I.V., Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. New Engl. J. Med. 372:26 (2015), 2499–2508.
112. Inoue, T., Hiratsuka, M., Osaki, M., Yamada, H., Kishimoto, I., Yamaguchi, S., Nakano, S., Katoh, M., Ito, H., Oshimura, M., SIRT2, a tubulin deacetylase, acts to block the entry to chromosome condensation in response to mitotic stress. Oncogene 26:7 (2007), 945–957.
113. Li, J., Yin, C., Okamoto, H., Mushlin, H., Balgley, B.M., Lee, C.S., Yuan, K., Ikejiri, B., Glasker, S., Vortmeyer, A.O., Identification of a novel proliferation-related protein, WHSC1 4a, in human gliomas. Neuro-Oncol. 10:1 (2008), 45–51.
114. Connolly, I.D., Li, Y., Gephart, M.H., Nagpal, S., The liquid biopsy: the role of circulating DNA and RNA in central nervous system tumors. Curr. Neurol. Neurosci. Rep. 16:3 (2016), 1–8.
115. Benesova, L., Belsanova, B., Suchanek, S., Kopeckova, M., Minarikova, P., Lipska, L., Levy, M., Visokai, V., Zavoral, M., Minarik, M., Mutation-based detection and monitoring of cell-free tumor DNA in peripheral blood of cancer patients. Anal. Biochem. 433:2 (2013), 227–234.
116. Newman, A.M., Bratman, S.V., To, J., Wynne, J.F., Eclov, N.C., Modlin, L.A., Liu, C.L., Neal, J.W., Wakelee, H.A., Merritt, R.E., An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat. Med. 20:5 (2014), 548–554.
117. Tanwar, M.K., Gilbert, M.R., Holland, E.C., Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma. Cancer Res. 62:15 (2002), 4364–4368.
118. Balaña, C., Ramirez, J.L., Taron, M., Roussos, Y., Ariza, A., Ballester, R., Sarries, C., Mendez, P., Sanchez, J.J., Rosell, R., O6-methyl-guanine-DNA methyltransferase methylation in serum and tumor DNA predicts response to 1, 3-bis (2-chloroethyl)-1-nitrosourea but not to temozolamide plus cisplatin in glioblastoma multiforme. Clin. Cancer Res. 9:4 (2003), 1461–1468.
119. Lavon, I., Refael, M., Zelikovitch, B., Shalom, E., Siegal, T., Serum DNA can define tumor-specific genetic and epigenetic markers in gliomas of various grades. Neuro-Oncol. 12:2 (2010), 173–180.
120. Ricci, S., Guadagno, E., Bruzzese, D., De Caro, M.D.B., Peca, C., Sgulò F.G., Maiuri, F., Di Carlo, A., Evaluation of matrix metalloproteinase type IV-collagenases in serum of patients with tumors of the central nervous system. J. Neurooncol., 2016, 1–10.
121. Shalaby, T., Achini, F., Grotzer, M.A., Targeting cerebrospinal fluid for discovery of brain cancer biomarkers. J. Cancer Metastasis Treat., 2, 2016, 177.
122. Khwaja, F.W., Nolen, J.D.L., Mendrinos, S.E., Lewis, M.M., Olson, J.J., Pohl, J., Van Meir, E.G., Ritchie, J.C., Brat, D.J., Proteomic analysis of cerebrospinal fluid discriminates malignant and nonmalignant disease of the central nervous system and identifies specific protein markers. Proteomics 6:23 (2006), 6277–6287.
123. Anoop, A., Singh, P.K., Jacob, R.S., Maji, S.K., CSF biomarkers for Alzheimer's disease diagnosis. Int. J. Alzheimer's Dis., 2010, 2010.
124. Wong, L.-J.C., Lueth, M., Li, X.-N., Lau, C.C., Vogel, H., Detection of mitochondrial DNA mutations in the tumor and cerebrospinal fluid of medulloblastoma patients. Cancer Res. 14 (2003), 3866–3871.
125. Liu, B.-L., Cheng, J.-X., Zhang, W., Zhang, X., Wang, R., Lin, H., Huo, J.-L., Cheng, H., Quantitative detection of multiple gene promoter hypermethylation in tumor tissue, serum, and cerebrospinal fluid predicts prognosis of malignant gliomas. Neuro-Oncol., 2010 (nop064).
126. Bettegowda, C., Sausen, M., Leary, R.J., Kinde, I., Wang, Y., Agrawal, N., Bartlett, B.R., Wang, H., Luber, B., Alani, R.M., Detection of circulating tumor DNA in early-and late-stage human malignancies. Sci. Transl. Med., 2014 (224ra24-224ra24).
127. Smith, E.R., Zurakowski, D., Saad, A., Scott, R.M., Moses, M.A., Urinary biomarkers predict brain tumor presence and response to therapy. Clin. Cancer Res. 14:8 (2008), 2378–2386.
128. Mathivanan, S., Ji, H., Simpson, R.J., Exosomes: extracellular organelles important in intercellular communication. J. Proteomics 73:10 (2010), 1907–1920.
129. Shao, H., Chung, J., Lee, K., Balaj, L., Min, C., Carter, B.S., Hochberg, F.H., Breakefield, X.O., Lee, H., Weissleder, R., Chip-based analysis of exosomal mRNA mediating drug resistance in glioblastoma. Nat. Commun., 6, 2015.
130. Harshyne, L.A., Nasca, B.J., Kenyon, L.C., Andrews, D.W., Hooper, D.C., Serum exosomes and cytokines promote a T-helper cell type 2 environment in the peripheral blood of glioblastoma patients. Neuro-Oncol., 2015, nov107.
131. Manterola, L., Guruceaga, E., Pérez-Larraya, J.G., González-Huarriz, M., Jauregui, P., Tejada, S., Diez-Valle, R., Segura, V., Samprón, N., Barrena, C., A small noncoding RNA signature found in exosomes of GBM patient serum as a diagnostic tool. Neuro-Oncol., 2014 (not218).
132. Cheshmi, H., Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. New Cell. Mol. Biotechnol. J. 1:3 (2011), 75–88.
133. Akers, J.C., Ramakrishnan, V., Kim, R., Skog, J., Nakano, I., Pingle, S., Kalinina, J., Hua, W., Kesari, S., Mao, Y., MiR-21 in the extracellular vesicles (EVs) of cerebrospinal fluid (CSF): a platform for glioblastoma biomarker development. PLoS One, 8(10), 2013, e78115.
134. Shao, H., Chung, J., Balaj, L., Charest, A., Bigner, D.D., Carter, B.S., Hochberg, F.H., Breakefield, X.O., Weissleder, R., Lee, H., Protein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapy. Nat. Med. 18:12 (2012), 1835–1840.
135. Cho, D.-Y., Lin, S.-Z., Yang, W.-K., Hsu, D.-M., Lin, H.-L., Lee, H.-C., Lee, W.-Y., Chiu, S.-C., The role of cancer stem cells (CD133+) in malignant gliomas. Cell Transplant. 20:1 (2011), 121–125.
136. Melguizo, C., Prados, J., González, B., Ortiz, R., Concha, A., Alvarez, P.J., Madeddu, R., Perazzoli, G., Oliver, J.A., López, R., MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy. J. Transl. Med., 10(1), 2012, 250.
137. Pfenninger, C.V., Roschupkina, T., Hertwig, F., Kottwitz, D., Englund, E., Bengzon, J., Jacobsen, S.E., Nuber, U.A., CD133 is not present on neurogenic astrocytes in the adult subventricular zone, but on embryonic neural stem cells, ependymal cells, and glioblastoma cells. Cancer Res. 67:12 (2007), 5727–5736.
138. Sun, Y., Kong, W., Falk, A., Hu, J., Zhou, L., Pollard, S., Smith, A., CD133 (Prominin) negative human neural stem cells are clonogenic and tripotent. PLoS One, 4(5), 2009, e5498.
139. Wu, X., Wu, F., Xu, D., Zhang, T., Prognostic significance of stem cell marker CD133 determined by promoter methylation but not by immunohistochemical expression in malignant gliomas. J. Neurooncol. 127:2 (2016), 221–232.
140. Boivin, D., Labbé D., Fontaine, N., Lamy, S., Beaulieu, É., Gingras, D., Béliveau, R., The stem cell marker CD133 (prominin-1) is phosphorylated on cytoplasmic tyrosine-828 and tyrosine-852 by Src and Fyn tyrosine kinases. Biochemistry 48:18 (2009), 3998–4007.
141. Taïeb, N., Maresca, M., Guo, X.-J., Garmy, N., Fantini, J., Yahi, N., The first extracellular domain of the tumour stem cell marker CD133 contains an antigenic ganglioside-binding motif. Cancer Lett. 278:2 (2009), 164–173.
142. Yan, X., Ma, L., Yi, D., Yoon, J.-g., Diercks, A., Foltz, G., Price, N.D., Hood, L.E., Tian, Q., A CD133-related gene expression signature identifies an aggressive glioblastoma subtype with excessive mutations. Proc. Natl. Acad. Sci. 4 (2011), 1591–1596.
143. Metellus, P., Nanni-Metellus, I., Delfino, C., Colin, C., Tchogandjian, A., Coulibaly, B., Fina, F., Loundou, A., Barrie, M., Chinot, O., Prognostic impact of CD133 mRNA expression in 48 glioblastoma patients treated with concomitant radiochemotherapy: a prospective patient cohort at a single institution. Ann. Surg. Oncol. 18:10 (2011), 2937–2945.
144. Clément, V., Dutoit, V., Marino, D., Dietrich, P.Y., Radovanovic, I., Limits of CD133 as a marker of glioma self-renewing cells. Int. J. Cancer 125:1 (2009), 244–248.
145. Wang, J., Sakariassen, P.Ø., Tsinkalovsky, O., Immervoll, H., Bøe, S.O., Svendsen, A., Prestegarden, L., Røsland, G., Thorsen, F., Stuhr, L., CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells. Int. J. Cancer 122:4 (2008), 761–768.
146. Dahlstrand, J., Collins, V.P., Lendahl, U., Expression of the class VI intermediate filament nestin in human central nervous system tumors. Cancer Res. 52:19 (1992), 5334–5341.
147. Almqvist, P.M., Mah, R., Lendahl, U., Jacobsson, B., Hendson, G., Immunohistochemical detection of nestin in pediatric brain tumors. J. Histochem. Cytochem. 50:2 (2002), 147–158.
148. Ishiwata, T., Teduka, K., Yamamoto, T., Kawahara, K., Matsuda, Y., Naito, Z., Neuroepithelial stem cell marker nestin regulates the migration, invasion and growth of human gliomas. Oncol. Rep. 26:1 (2011), 91–99.
149. Lu, W.J., Lan, F., He, Q., Lee, A., Tang, C.Z., Dong, L., Lan, B., Ma, X., Wu, J.C., Shen, L., Inducible expression of stem cell associated intermediate filament nestin reveals an important role in glioblastoma carcinogenesis. Int. J. Cancer 128:2 (2011), 343–351.
150. Reimer, R., Helmbold, H., Szalay, B., Hagel, C., Hohenberg, H., Deppert, W., Bohn, W., Nestin modulates glucocorticoid receptor function by cytoplasmic anchoring. PLoS One, 4(6), 2009, e6084.
151. Wu, B., Sun, C., Feng, F., Ge, M., Xia, L., Do relevant markers of cancer stem cells CD133 and Nestin indicate a poor prognosis in glioma patients? A systematic review and meta-analysis. J. Exp. Clin. Cancer Res., 34(1), 2015, 44.
152. Kiessling, A., Rieger, M.A., Schackert, G., Schackert, H.K., Rieber, E.P., Highly specific overexpression of the transcription factor SOXll in human malignant gliomas. Oncol. Rep. 13 (2005), 139–144.
153. Annovazzi, L., Mellai, M., Caldera, V., Valente, G., Schiffer, D., SOX2 expression and amplification in gliomas and glioma cell lines. Cancer Genomics-Proteomics 8:3 (2011), 139–147.
154. Schmitz, M., Temme, A., Senner, V., Ebner, R., Schwind, S., Stevanovic, S., Wehner, R., Schackert, G., Schackert, H., Fussel, M., Identification of SOX2 as a novel glioma-associated antigen and potential target for T cell-based immunotherapy. Br. J. Cancer 96:8 (2007), 1293–1301.
155. Alonso, M.M., Diez-Valle, R., Manterola, L., Rubio, A., Liu, D., Cortes-Santiago, N., Urquiza, L., Jauregi, P., de Munain, A.L., Sampron, N., Genetic and epigenetic modifications of Sox2 contribute to the invasive phenotype of malignant gliomas. PLoS One, 6(11), 2011, e26740.
156. Cox, J.L., Wilder, P.J., Desler, M., Rizzino, A., Elevating SOX2 levels deleteriously affects the growth of medulloblastoma and glioblastoma cells. PLoS One, 7(8), 2012, e44087.
157. Singh, S.K., Manoranjan, B., Venugopal, C., Vora, P., McFarlane, N., Garg, N., Singh, M., Mann, A., Bakhshinyan, D., Mahendran, S., Sox2 identifies the treatment-refractory stem cell population in group 2 medulloblastoma. Neuro-Oncol., 16(Suppl. 3), 2014 (iii5-iii5).
158. Favaro, R., Appolloni, I., Pellegatta, S., Sanga, A.B., Pagella, P., Gambini, E., Pisati, F., Ottolenghi, S., Foti, M., Finocchiaro, G., Sox2 is required to maintain cancer stem cells in a mouse model of high-grade oligodendroglioma. Cancer Res. 74:6 (2014), 1833–1844.
159. Gangemi, R.M.R., Griffero, F., Marubbi, D., Perera, M., Capra, M.C., Malatesta, P., Ravetti, G.L., Zona, G.L., Daga, A., Corte, G., SOX2 silencing in glioblastoma tumor-initiating cells causes stop of proliferation and loss of tumorigenicity. Stem Cells 27:1 (2009), 40–48.
160. Restall, I., Luchman, H.A., Weiss, S., STAT3 Is a Central Regulator of Proliferation Invasion and Metabolism in GBM Tumor Initiating Cells. 2016, AACR.
161. Weiss, S., Nguyen, S., Luchman, A., Grinshtein, N., Stechishin, O., Aman, A., Uehling, D., al-Awar, R., Kaplan, D., Brain tumour initiating cells and targeting stat3 oncogenic signalling in Gbm. Neuro-Oncol., 16(Suppl. 3), 2014 (iii35-iii35).
162. Nakata, S., Campos, B., Bageritz, J., Lorenzo Bermejo, J., Becker, N., Engel, F., Acker, T., Momma, S., Herold-Mende, C., Lichter, P., LGR5 is a marker of poor prognosis in glioblastoma and is required for survival of brain cancer stem-like cells. Brain Pathol. 23:1 (2013), 60–72.
163. Pietras, A., Katz, A.M., Ekström, E.J., Wee, B., Halliday, J.J., Pitter, K.L., Werbeck, J.L., Amankulor, N.M., Huse, J.T., Holland, E.C., Osteopontin-CD44 signaling in the glioma perivascular niche enhances cancer stem cell phenotypes and promotes aggressive tumor growth. Cell Stem Cell 14:3 (2014), 357–369.
164. Clement, V., Sanchez, P., De Tribolet, N., Radovanovic, I., i Altaba, A.R., HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity. Curr. Biol. 17:2 (2007), 165–172.
165. Chang, C.-J., Hsu, C.-C., Yung, M.-C., Chen, K.-Y., Tzao, C., Wu, W.-F., Chou, H.-Y., Lee, Y.-Y., Lu, K.-H., Chiou, S.-H., Enhanced radiosensitivity and radiation-induced apoptosis in glioma CD133-positive cells by knockdown of SirT1 expression. Biochem. Biophys. Res. Commun. 380:2 (2009), 236–242.
166. Ludwig, K., Kornblum, H.I., Molecular markers in glioma. J. Neurooncol., 2017, 1–8.
167. Patel, A.P., Tirosh, I., Trombetta, J.J., Shalek, A.K., Gillespie, S.M., Wakimoto, H., Cahill, D.P., Nahed, B.V., Curry, W.T., Martuza, R.L., Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 344:6190 (2014), 1396–1401.
168. Kulasingam, V., Diamandis, E.P., Strategies for discovering novel cancer biomarkers through utilization of emerging technologies. Nat. Clin. Pract. Oncol. 5:10 (2008), 588–599.
169. Zolg, J.W., Langen, H., How industry is approaching the search for new diagnostic markers and biomarkers. Mol. Cell. Proteomics 3:4 (2004), 345–354.
170. Carlsson, S.K., Brothers, S.P., Wahlestedt, C., Emerging treatment strategies for glioblastoma multiforme. EMBO Mol. Med. 6:11 (2014), 1359–1370.
171. Mamluk, R., Carvajal, I.M., Morse, B.A., Wong, H.K., Abramowitz, J., Aslanian, S., Lim, A.-C., Gokemeijer, J., Storek, M.J., Lee, J., Anti-tumor effect of CT-322 as an adnectin inhibitor of vascular endothelial growth factor receptor-2. MAbs, 2010, 199–208 (Taylor & Francis).
172. Bogdahn, U., Hau, P., Stockhammer, G., Venkataramana, N., Mahapatra, A., Suri, A.a., Balasubramaniam, A., Nair, S., Oliushine, V., Parfenov, V., Targeted therapy for high-grade glioma with the TGF-β2 inhibitor trabedersen: results of a randomized and controlled phase IIb study. Neuro-Oncol. 1 (2011), 132–142.
173. Roychowdhury, S., Iyer, M.K., Robinson, D.R., Lonigro, R.J., Wu, Y.-M., Cao, X., Kalyana-Sundaram, S., Sam, L., Balbin, O.A., Quist, M.J., Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci. Transl. Med., 3(111), 2011 (111ra121-111ra121).
174. Ramaswamy, S., Translating cancer genomics into clinical oncology. New Engl. J. Med. 350:18 (2004), 1814–1816.
175. Szopa, W., Burley, T.A., Kramer-Marek, G., Kaspera, W., Diagnostic and therapeutic biomarkers for glioblastoma: current status and future perspectives. BioMed Res. Int., 2017, 13.